IPH2101
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for IPH2101, covering 2014-02-28 to 2016-03-24. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma [Phase 2]